scorecardresearch
Add as a preferred source on Google
Friday, December 12, 2025
TopicIndia pharma industry

Topic: india pharma industry

Big pharma pivoting to more lucrative obesity segment, Indian drugmakers eye insulin market

The size of India’s insulin market was an estimated Rs 4,404 crore in April this year, with Indian players making steady entry into a market once dominated by Big pharma.

Why Trump’s executive order lowering prescription drug prices won’t rattle Indian pharma industry

The order aims to slash drug prices by up to 80%. Indian industry had been on edge since March amid threats of reciprocal tariff on pharmaceutical products.

How reciprocal Trump tariffs may impact Indian pharma, and become a bitter pill for the US

Spooked by US president's threat, several Indian pharma players lobby for blanket duty waiver on drugs coming from America, with chunk of their earnings hinging on exports to the country.

Hyderabad will be India’s life sciences capital, says CM Reddy as BioAsia 2025 kicks off

Telangana CM says his government will create 'pharma villages', potentially creating over 5 lakh jobs, and is also considering a dedicated life sciences policy.

24 mega-seller drugs set to lose patents in US, big opportunity for Indian drugmakers — govt report

Patent expiry would mean that drugmakers will be able to launch generic versions of the blockbuster drugs, which are typically priced up to 90 percent lower than their innovator drug.

No conferences in foreign locales, no gifts or hospitality — govt’s new marketing code for drugmakers

Uniform Code for Pharmaceutical Marketing Practices 2024, which replaces a 2015 code, remains voluntary, with its implementation watched by ethics panel constituted by pharma associations.

‘Can hamper entry of new drugs’ — groups raise alarm over IP proposals part of India-EFTA talks

India & EFTA (Iceland, Liechtenstein, Norway and Switzerland) are negotiating Trade and Economic Partnership Agreement (TEPA) that is likely to be finalized within next few weeks.

‘Adulterated drugs’ to breakthrough cancer therapy — how India’s health & pharma sector fared in 2023

The year was eventful with National Medical Commission's flip-flops over controversial decisions, tightening of various norms and launch of made-in-India drugs to treat rare diseases.

Indian pharma market can more than treble by 2030, says industry report, urges focus on quality

Report by Organisation of Pharmaceutical Producers of India and Ernst & Young says growth could be propelled by expansion in the domestic market, spurred by India's economic growth.

70% of antibiotic fixed-dose combination drugs sold in India unapproved or banned, finds study

Govt’s moves to curb irrational fixed-dose combinations may have been insufficient & lack enforcement, say researchers. Study published in Journal of Pharmaceutical Policy and Practice.

On Camera

IndiGo cancellations made TV news do the unexpected — question the Modi government

Republic TV was the harshest of them all: “The (civil aviation) minister has done a bad job,” said prime time anchor Arnab Goswami.

IndiGo’s profits dipped, most airlines sunk into losses last fiscal even as flier numbers soared

Despite growing passenger volume, 11 out of 14 carriers reported losses in 2023-24. IndiGo recorded profit of Rs 8,167 crore, which reduced to Rs 7.253 crore in 2024-25.

Dubai Tejas crash revives focus on advanced, fully automated safety systems

Dubai airshow crash & pilot death have rekindled concerns over pilot safety, and need for smarter automated systems that can step in when G-forces, temporary loss of consciousness hit the pilot.

Asim Munir & Pakistan’s Failed Marshal Doctrine

None of Pakistan’s PMs has lasted 5 years. That the current PM has given Asim Munir 5 years shows that of all military dictatorships history has seen, Pakistan’s is most creative.